Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Change in Receivables (2016 - 2025)

Nephros (NEPH) has 16 years of Change in Receivables data on record, last reported at $621000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables rose 432.09% year-over-year to $621000.0; the TTM value through Sep 2025 reached $970000.0, up 295.92%, while the annual FY2024 figure was $285000.0, 28.96% up from the prior year.
  • Change in Receivables reached $621000.0 in Q3 2025 per NEPH's latest filing, up from -$637000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $896000.0 in Q1 2025 and bottomed at -$756000.0 in Q3 2022.
  • Average Change in Receivables over 5 years is $68789.5, with a median of $50000.0 recorded in 2023.
  • Peak YoY movement for Change in Receivables: tumbled 539.53% in 2022, then skyrocketed 3972.73% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $87000.0 in 2021, then crashed by 201.15% to -$88000.0 in 2022, then surged by 156.82% to $50000.0 in 2023, then skyrocketed by 80.0% to $90000.0 in 2024, then soared by 590.0% to $621000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $621000.0 in Q3 2025, -$637000.0 in Q2 2025, and $896000.0 in Q1 2025.